Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis
Mutations in the cystic fibrosis transmembrane conductance regulator (<i>CFTR)</i> gene decrease the structural stability and function of the CFTR protein, resulting in cystic fibrosis. Recently, the effect of CFTR-targeting combination therapy has dramatically increased, and it is expec...
Main Authors: | Ryosuke Fukuda, Tsukasa Okiyoneda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/4/75 |
Similar Items
-
'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations
by: Knowles Michael R, et al.
Published: (2001-08-01) -
Effectiveness and Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Children With Cystic Fibrosis: A Meta-Analysis
by: Qiyu Li, et al.
Published: (2022-06-01) -
Corneal Refractive Surgery Considerations in Patients with Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders
by: Moshirfar M, et al.
Published: (2022-11-01) -
Functional Consequences of CFTR Interactions in Cystic Fibrosis
by: Yashaswini Ramananda, et al.
Published: (2024-03-01) -
Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials
by: Yizi Wang, et al.
Published: (2022-03-01)